Skip to main content


Over one billion people suffer from neurological and mental disorders. We aim to help.

Metallomix is an innovative biopharmaceutical company building a pipeline of novel drugs based upon the use of cold isotopes facilitated by its proprietary isotope-selective modulation methods. The medicines we are developing are aimed to alleviate suffering, improve motor and cognitive functions, and enhance survival. 

Investor Relations
Direct: (917) 536-1327      
eMail: IR[at]